Osteopore
Osteopore (ASX: OSX) is a Singapore-based medical device company that develops and sells 3D-printed bioresorbable PCL bone regeneration implants for craniofacial, orbital, dental, orthopaedic and aesthetic rhinoplasty surgery, distributed through a global channel-partner network.
- Company typePublic
- Founded2003
- HeadquartersSingapore, Singapore
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Osteopore does
Osteopore is a Singapore-headquartered, ASX-listed medical device company (ASX: OSX) that develops and commercializes 3D-printed bioresorbable bone regeneration implants. Its core technology is a proprietary polycaprolactone (PCL) scaffold fabricated with patented additive manufacturing techniques, producing micro-structured implants with interconnected pores that dissolve over time and are replaced by natural host bone. The product portfolio centers on the Osteopore PCL Scaffold family, including Osteoplug and Osteoplug-C for neurosurgical burr hole repair, Osteomesh and PC11 for orbital floor reconstruction, the PC17/18/22/23/24 Osteostrip variants for cranial reconstruction, PC60 for orbital floor use, and patient-specific implants designed from CT scan data. Use cases span craniofacial, orbital, dental/oral, orthopaedic, and aesthetic rhinoplasty surgical specialties.
Osteopore is the first company globally to obtain regulatory authorization for 3D-printed bone scaffolds and reports regulatory approvals across nine jurisdictions, with 120,000+ successful cases and 150+ peer-reviewed publications supporting the technology. Revenue is generated primarily through B2B sales of these disposable implants to hospitals and surgeons, augmented by an expanding digital surgical planning and additive manufacturing services line. Go-to-market is hybrid: direct field sales combined with exclusive distribution partnerships — most notably Zimmer Biomet (craniofacial, 2023), Essex Bio-Technology (dental, 2025), and Kelyniam Inc. for the US (May 2025) — alongside a network of 23 regional distributors across 20+ countries.
The business remains sub-scale: FY2024 revenue was approximately AUD 2.76 million with 24.6% year-over-year growth, against operating losses of about AUD 3.35 million, with market capitalization near historic lows around AUD 3.94 million. Recent strategic moves tilt toward platform expansion rather than single-product scaling, including a Singapore 3D printing services launch (February 2026), a planned second Center of Excellence at the University of Hong Kong, and active collaboration in an A$18.7m A*STAR/NDCS dental R&D project.
Osteopore firmographics
Firmographics- Name
- Osteopore
- Legal name
- Osteopore International Pte. Ltd.
- Website
- https://osteopore.com
- Company type
- Public
- Founded year
- 2003
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Osteopore (ASX: OSX) is a Singapore-based medical device company that develops and sells 3D-printed bioresorbable PCL bone regeneration implants for craniofacial, orbital, dental, orthopaedic and aesthetic rhinoplasty surgery, distributed through a global channel-partner network.
- Ownership category
- akta.pro rank
Osteopore industry classification
Industry- Product category
- Bioresorbable Bone Regeneration Implants
- NAICS
- Dental Equipment and Supplies Manufacturing (339114), Dental Laboratories (339116)
- SIC
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
- akta.pro primary industry
- 3D-Printed & Patient-Specific Implants (Custom Ortho/Spine/Cranial) (HLAHAEAJ)
- akta.pro secondary industries
- Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials) (HLAAAGAB), Medical & Dental 3D Printing Services (patient-specific devices, dental labs) (IMAAADAG), Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG), 3D Printing/Additive Manufacturing for Dental Prosthetics (HLABAJAF)
Keywords
Where Osteopore is headquartered
LocationHeadquarters
- HQ city
- Singapore
- HQ country
- Singapore
- HQ region
- Asia
Offices3 records
Markets served
Osteopore business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Others
Revenue model
- Biodegradable Implant Products: Sale of 3D-printed bioresorbable bone scaffolds including products for cranial reconstruction (Osteoplug, Osteoplug-C, PC17, PC18, PC22, PC23, PC24), orbital reconstruction (Osteomesh, PC11, PC60), and patient-specific implants. Products are sold through direct sales and distribution partners globally.
- 3D Printing Services: New service line offering digital surgical planning, customized design, and additive manufacturing services to hospitals and healthcare providers. Aims to create higher-value revenue streams by expanding beyond implant manufacturing.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Medical device pricing - quote based |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels5 records
Osteopore product offering
Product offeringCore offering
Osteopore designs, manufactures, and commercializes 3D-printed bioresorbable bone scaffolds made from polycaprolactone (PCL) polymer for surgical use in cranial, orbital, dental, orthopaedic, and rhinoplasty applications. The company also offers patient-specific customized implants and is expanding into 3D printing services such as digital surgical planning and additive manufacturing for hospitals and surgeons.
Product overview
Osteopore offers a portfolio of 3D-printed bioresorbable bone regeneration implants based on proprietary polycaprolactone (PCL) scaffold technology. The core product line includes the Osteopore PCL Scaffold™ family for general bone void filling, with specialized variants such as Osteoplug® and Osteoplug®-C for neurosurgical burr hole repair, and Osteomesh® for orbital reconstruction. Patient-specific customization is available via CT scan-based design. The company has expanded into digital surgical planning and additive manufacturing services. All products bioresorb over time, leaving only natural healthy bone tissue.
Differentiator
Problem solved
Functional benefit
Brands
- Osteomesh: Biodegradable mesh product for orbital reconstruction and other surgical applications
- Osteoplug
- Osteoplug-C
- PC11
- PC17
- PC18
- PC22
- PC23
- PC24
- PC60
- Osteopore PCL Scaffold
Products and services
- Osteoplug® Bioresorbable bone void filler made from polycaprolactone (PCL) polymer for burr hole repair in neurosurgical procedures; naturally dissolves over time allowing natural bone regeneration.
- Osteoplug®-C Bioresorbable burr hole repair device available in various shapes and sizes, specifically designed to allow placement of catheters during neurosurgical procedures.
- Osteomesh® Biosturable PCL mesh implant for orbital floor reconstruction with interconnected porous structure that supports tissue regeneration while gradually bioresorbing.
- Patient Specific Implant Customized 3D-printed bone implants designed from individual patient CT scan data for complex craniofacial reconstruction cases where standard off-the-shelf implants are unsuitable.
- Osteopore PCL Scaffold™ Flagship bone void filler made from polycaprolactone polymer for repair of neurosurgical burr holes, craniotomy cuts, cranial defects, and augmentation or restoration of bony contour in the craniofacial skeleton; first 3D-printed bone scaffold to receive market authorization worldwide.
- 3D Printing Services (Singapore) Digital surgical planning, customized implant design, and additive manufacturing services for hospitals and healthcare providers; aims to improve surgical precision, reduce lead times, and optimize hospital resource use.
Quantifiable outcome
- 24.6% year-over-year revenue growth in 2024
- +3 more outcomes
Companies that use Osteopore
Customer profileNamed customers4 records
Segments5 records
Ideal customer profiles5 records
Osteopore technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Osteopore partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core, flagship, major and minor.
- Kelyniam Inc.coreIn May 2025, Kelyniam Inc., a US healthcare technology company, formed a partnership with Osteopore Limited to enhance production, distribution, and regulatory compliance of Osteopore's biodegradable implant products in the US market. This partnership supports Osteopore's market entry and expansion in the United States.
- Essex Bio-Technology LimitedcoreEssex Bio-Technology holds exclusive distribution agreements for Osteopore's dental products. Essex Bio-Technology reported revenue growth of 8.6% to HK$1,813.8 million in 2025, driven by its flagship products. The partnership expands Osteopore's dental product reach through an established biotech distribution network.
- Zimmer BiometflagshipOsteopore struck an Exclusive Distribution Agreement with Zimmer Biomet for its craniofacial products. Zimmer Biomet is a major global orthopaedic company, making this a flagship partnership for Osteopore's craniofacial product line.
- University of Hong KongcoreOsteopore confirmed plans to open a second global center of excellence at the University of Hong Kong. This follows the first center established at Singapore General Hospital. Centers of excellence focus on digital surgical planning, customized design, and additive manufacturing services.
- Singapore General HospitalcoreOsteopore and SingHealth (Singapore Health Services) partnered on a Global Centre of Excellence at Singapore General Hospital. This represents the first center of excellence and a key strategic partnership for clinical collaboration and innovation.
- A*STAR (Agency for Science, Technology and Research)majorOsteopore is involved in an A$18.7m project with NDCS (National Dental Centre Singapore) and A*STAR that has hit key milestones. This represents significant government and research institution collaboration in Singapore's medtech ecosystem.
- National Dental Centre Singapore (NDCS)majorCollaboration on the A$18.7m project with Osteopore and A*STAR for dental research and development. NDCS represents a key clinical partner for dental product development and clinical studies.
- University of ChileminorOsteopore and the University of Chile successfully completed pre-clinical bone implant studies showing significant advancements in speeding up bone regeneration. This represents international academic collaboration for clinical validation.
- KenvueminorEssex Bio-Technology Limited has a collaboration with Kenvue for consumer health products. While not a direct Osteopore partnership, this is noted within the Essex Bio-Technology ecosystem.
Scale indicators8 records
Recent moves8 records
Expansion highlights7 records
Osteopore competitors and assessment
Company assessmentDirect peers
- Renishaw: Renishaw's healthcare division manufactures 3D-printed medical implants and craniomaxillofacial patient-specific devices, overlapping Osteopore's cranial and dental implant portfolio.
- Materialise: Materialise offers 3D printing services, software, and patient-specific medical devices, including personalized implants and surgical planning — directly overlapping Osteopore's pivot into digital surgical planning and customized implant manufacturing.
- Xilloc: Xilloc manufactures patient-specific 3D-printed implants (notably CMF/cranial and orthopedic), making it a direct functional peer to Osteopore's patient-specific craniofacial and orbital implant business.
- Stratasys: Stratasys supplies 3D printing systems and validated medical workflows for anatomical models, surgical guides, and patient-specific devices — overlapping Osteopore's 3D printing services and additive manufacturing capabilities.
- OssDsign: OssDsign develops bioresorbable bone grafts and patient-specific craniofacial implants; both companies compete in regenerative bone substitutes used for cranial and orthopedic reconstruction.
Broad incumbents
- Zimmer Biomet: Zimmer Biomet is Osteopore's exclusive distributor for craniofacial products and is itself a global orthopedic and CMF implant incumbent; the partnership-cum-competition dynamic makes it a key comparable.
- Stryker: Stryker has an established CMF and orthobiologics portfolio (including 3D-printed Tritanium implants) and competes broadly with Osteopore in regenerative bone and cranial reconstruction markets.
- 3D Systems (Healthcare): 3D Systems' healthcare segment offers 3D-printed anatomical models, surgical planning, and personalized implants. As a much larger, diversified 3D printing incumbent, it competes broadly across Osteopore's clinical and service workflows.
- DePuy Synthes (Johnson & Johnson MedTech): DePuy Synthes is a global leader in CMF and orthopedic implants and trauma, representing a broad incumbent competing across the same surgical specialties Osteopore serves.
Emerging players
- Corin: Corin is an emerging orthopedic technology player with growing focus on personalization and biologic-enhanced implants, adjacent to Osteopore's patient-specific, regenerative positioning in orthopedics.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Osteopore social profiles
Digital presenceOsteopore compliance and trust
Trust signalCompliance1 record
Osteopore financial estimates
Financial estimateRevenue estimate
Valuation estimate
Osteopore leadership team
Management profileNumber of profiles
Profiles7 records
Osteopore subsidiaries and ownership
Company hierarchySubsidiaries1 record
Osteopore funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Osteopore M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Osteopore
What does Osteopore do?
Osteopore designs, manufactures, and commercializes 3D-printed bioresorbable bone scaffolds made from polycaprolactone (PCL) polymer for surgical use in cranial, orbital, dental, orthopaedic, and rhinoplasty applications. The company also offers patient-specific customized implants and is expanding into 3D printing services such as digital surgical planning and additive manufacturing for hospitals and surgeons.
Is Osteopore a public or private company?
Osteopore is a public company. It is classified as public and is currently operating.
When was Osteopore founded?
Osteopore was founded in 2003. It employs 11 to 50 people.
Where is Osteopore based?
Osteopore is headquartered in Singapore, Singapore, in the Asia region.
How does Osteopore make money?
Two revenue lines are on record. Biodegradable Implant Products are the primary driver. The others are 3D Printing Services.
Who are Osteopore's main competitors?
Direct peers on record are Renishaw, Materialise, Xilloc, Stratasys and OssDsign. Broad incumbents are Zimmer Biomet, Stryker, 3D Systems (Healthcare) and DePuy Synthes (Johnson & Johnson MedTech). Corin is listed as an emerging player.
Does Osteopore have an API?
No public API is recorded for Osteopore.
What industry is Osteopore in?
Osteopore's product category is Bioresorbable Bone Regeneration Implants. Its primary akta.pro industry code is HLAHAEAJ, 3D-Printed & Patient-Specific Implants (Custom Ortho/Spine/Cranial), with a secondary code of HLAAAGAB, Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials). Its NAICS code is 339114 and its SIC code is 3842.